Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis

COVID‐19 carries a high risk of severe disease course, particularly in patients with comorbidities. Therapy of severe COVID‐19 infection has relied on supportive intensive care measures. More specific approaches including drugs that limit the detrimental “cytokine storm”, such as Janus‐activated kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Koschmieder, Steffen, Jost, Edgar, Cornelissen, Christian, Müller, Tobias, Schulze‐Hagen, Maximilian, Bickenbach, Johannes, Marx, Gernot, Kleines, Michael, Marx, Nikolaus, Brümmendorf, Tim H., Dreher, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361537/
https://www.ncbi.nlm.nih.gov/pubmed/32593209
http://dx.doi.org/10.1111/ejh.13480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361537/
https://www.ncbi.nlm.nih.gov/pubmed/32593209
http://dx.doi.org/10.1111/ejh.13480

Ejemplares similares